Bernstein SocGen raises Natera stock price target to $205 on strong revenue

Published 08/08/2025, 14:16
Bernstein SocGen raises Natera stock price target to $205 on strong revenue

Investing.com - Bernstein SocGen Group raised its price target on Natera (NASDAQ:NTRA) to $205.00 from $200.00 on Friday, while maintaining an Outperform rating on the genetic testing company’s stock. Currently trading at $141.08, Natera has shown strong momentum with a 31% return over the past year, according to InvestingPro data.

The price target adjustment follows Natera’s reported total revenues of $547 million, which exceeded consensus estimates of $476 million by 15%. The company has demonstrated impressive revenue growth of 51.5% over the last twelve months, with total revenue reaching $1.83 billion. InvestingPro analysis reveals 8 additional key insights about Natera’s financial performance.

Natera posted gross margins of 63.4% reported, or 60.4% on a repeatable basis when excluding a 3 percentage point true-up benefit, which fell below consensus estimates of 61.3%.

The company has raised its revenue guidance to a range of $2,020-$2,100 million for the current fiscal year.

Natera maintained its operating expense guidance unchanged despite the revenue outlook increase, according to Bernstein SocGen.

In other recent news, Natera reported its second-quarter 2025 earnings, revealing a strong revenue performance that exceeded expectations. The company announced a revenue of $546.6 million, surpassing forecasts by 14.85%, though its earnings per share (EPS) came in at -$0.74, missing the anticipated -$0.62. Despite the EPS miss, the market responded favorably, likely due to the robust revenue growth. Following the earnings announcement, TD Cowen raised its price target for Natera from $200 to $215, maintaining a Buy rating on the stock. This adjustment reflects the company’s strong performance across key metrics. These recent developments have generated positive sentiment around Natera, as evidenced by the stock’s upward movement in response to the earnings report.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.